Talk:Tissue plasminogen activator
From Wikipedia, the free encyclopedia
 |
This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess. |
| Start | This page has been rated as Start-Class on the quality assessment scale |
| Low | This article has been rated as Low-importance on the importance assessment scale |
 |
This article is within the scope of the Molecular and Cellular Biology WikiProject. To participate, visit the WikiProject for more information. The WikiProject's current monthly collaboration is focused on improving Restriction enzyme. | ||
|
Article Grading: The article has not been rated for quality and/or importance yet. Please rate the article and then leave comments here to explain the ratings and/or to identify the strengths and weaknesses of the article. Click here for an overview of how to rate this article. |
|||
In accordance with Wikipedia:WikiProject_Drugs naming policy, I propose we move this page to the INN alteplase. If you have any concern with this proposal, please discuss it on this page. Matt 23:15, 21 Dec 2004 (UTC)
- Since tPA is primarily a human protein, and only secondarily a drug, I don't think that would be a good thing to do. AttishOculus 07:59, 29 December 2006 (UTC)
-
- I also think that a recombinant drug shouldn't overtake the physiological protein in significance. We have a precedent in Epogen, that is, recombinant Erythropoietin, which is redirected to the physiological chemical from that search. In most cases this seems reasonable as physiological chemicals administered exogenously have similar effects to their endogenous counterparts (although not the same: e.g. exogenous insulin). A second page just for the drug would be double handling, but I do also agree that the Drug usage needs to be addressed formally. Maybe a second Major Heading further down the page "Alteplase: recombinant Tissue Plasminogen Activator" and a wikiproject drugs format be followed there. I suggest that this will become of increasing importance as more recombiinant drugs appear, and new drugs like alteplase may carry a different moniker than the endogenous protein. This may even be important enough to bring up in Wikipedia:WikiProject_Drugs and Wikipedia:WikiProject Molecular and Cellular Biology if it is not already being hotly debated there.Markjohndaley 15:25, 10 June 2007 (UTC)
